

Today's issue of PD

Pharmacy Daily today has two pages of news plus the latest MIMS Monthly Update.

Click and Conceive+

Pharmacy Click & Collect

GLOBAL personal care company Sasmar has listed its Australian product range with the Pharmacy Guild of Australia's Pharmacy Click and Collect platform.

Conceive Plus, a bespoke product that can help facilitate the process of conception, is another tool for pharmacists in the family planning category.

With Conceive Plus's popularity growing, the company felt it essential to direct these customers from the Conceive Plus website directly to their local community pharmacy stockist.



The Pharmacy Click and Collect platform has close to 1,100 network pharmacies and is free and exclusive to Guild member pharmacies.

In addition, Sasmar will connect its Personal Lubricant range giving pharmacies and consumers additional options for eCommerce sales.

Guild member pharmacies are encouraged to activate their free subscription to Pharmacy Click and Collect by [CLICKING HERE](#).

Banana Boat vindicated

THE suppliers of Banana Boat sunscreens have welcomed the withdrawal of a potential class action lawsuit by Bannister Legal (**PD** breaking news), saying the proposed case was based on "unreliable claims about the performance of Banana Boat aerosol products".

The Bannister case, which has now been removed from the law firm's website, claimed to represent a "string of angry consumers" who said they had been sunburnt after using Banana Boat aerosol products.

Edgewell Personal Care had categorically refuted the claims and stood behind the products (**PD** 23 Nov 2017), with poor testing results claimed by the law firm "entirely

inconsistent" with other analyses undertaken by "independent, reputable labs".

Edgewell regional vice president Ivan Nuich said consumers had recently been subjected to a number of false and misleading reports based on unreliable sources.

"We needed to vigorously contest these unfair claims because it's important for consumers to be able to trust Banana Boat sunscreens.

"We were prepared to defend ourselves in court if necessary."

Earlier this week the Therapeutic Goods Administration published the outcome of a review of commonly sold sunscreens, saying it had found no compliance deficiencies (**PD** Tue).

In particular, SPF testing supported claims on aerosol sunscreens and confirmed all products are only effective if applied correctly.

Drugmakers stockpile ahead of Brexit

TWO of the world's biggest drug firms are stockpiling medicines in case of supply disruptions after Brexit, according to *BBC* and *Wall Street Journal* reports.

France's Sanofi is increasing its stocks by a month to give it a 14 week supply of medicines while Switzerland's Novartis said it was also preparing for the possibility of a no-deal Brexit.

Sanofi, which makes insulin, said it is worried about any transport delays following Brexit, as most of its supplies have to cross the English Channel.

Earlier in Jul the UK NHS said it was preparing to stockpile drugs as well, in case of a "no deal" Brexit.

SGLT2 inhibitors nod

LANDMARK research that revealed the cardiovascular benefits of empagliflozin2 (Jardiance by Boehringer Ingelheim) in people with type 2 diabetes and established cardiovascular disease has resulted in new guidelines recommending the product class.

Sodium glucose cotransporter 2 (SGLT2) class of medicines, which inhibit reabsorption of glucose in the kidney, now have a specific role described in new guidelines by the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand.

[CLICK HERE](#) for the guidelines.

Wheelchair takeover

MELBOURNE-BASED wheelchair manufacturer Magic Mobility has been acquired by international firm Sunrise Medical.

The Australian company was established 24 years ago by Ashley Daff, with the firm's key focus to put the power into the hands of those who have a disability.

Sunrise Medical offers a wide range of products including manual and electric wheelchairs, scooters, seating and other items.

All existing jobs will be retained, with potential for expansion, while the Magic Mobility brand will also be retained.

Fairy capsule alert

A PRODUCT called Fairy Capsules purchased online by a number of people in Australia has been found to contain the undeclared substance sibutramine.

The Therapeutic Goods Administration said the prescription only substance was withdrawn globally in 2010 due to increased risk of cardiac events and stroke.

Condom withdrawal

RECKITT Benckiser is conducting a recall of one batch of Durex Real Feel polyisoprene (non-latex) condoms which has been found to be unlikely to meet specifications at the end of its shelf-life in 2021.

The recall mirrors similar action overseas (**PD** Wed) and follows in-house durability testing by RB, with the affected condoms coming from batch number 1000432443 expiring in Jan 2021.



Equip yourself with the latest essential skills to maximise your career potential

Put your career into gear today!



www.psa.org.au/career-essentials-program

Your Pharmacy Recruitment Experts

FreeCall: 1800 429 829
Email: info@ravensrecruitment.com.au
Web: www.ravensrecruitment.com.au

Jobs of the Week

- **Pharmacist** - Mornington Peninsula, VIC (Job# 200015992)
Monday to Friday roster; \$40/hr + fuel card!!!
- **Pharmacist in Charge** - South Coast, NSW (Job# 200030750)
Partnership will be yours flexible roster beautiful locale.
- **Pharmacist Manager** - Gold Coast, QLD (Job# 200030808)
5 days/wk roster; forward pharmacy model; awesome team!

Looking for a different direction for your career? We can help!

Stay up to date
on the go

Download the app



Dispensary Corner

DAMNED if you do - drammed if you don't!

When it comes to drinking alcohol, both long term abstinence and heavy drinking may increase dementia risk, but for different reasons, according to new research published in the *British Medical Journal*.

People who either abstain from alcohol - or consume more than 14 units a week - during middle age are at increased risk of developing dementia, French and UK researchers found.

In abstainers, increased risks were attributed in some measure to increased rates of cardiometabolic disease.

Now about that nightcap habit...

CLICK HERE for the research.



A RUSSIAN man has died in a bizarre bathroom accident, after slipping over and landing on a toilet brush which tragically stabbed him through the eye.

The incident took place in the town of Istra near Moscow, with the *Moskovsky Komsomolets* newspaper reporting the 60-year-old was rushed to hospital to have the implement removed.

Unfortunately his skull had to be opened to give access to the toilet brush handle, and the head surgery left him in a coma.

He was moved to a hospital closer to home for further treatment, but sadly never regained consciousness and died a few days later.

Medicinal agriculture



LA TROBE University has announced that its Melbourne campus in Bundoora will be the site for Australia's first Research Hub for Medicinal Agriculture.

The \$27+ million initiative will combine extensive research and industry expertise to create new jobs and drive better health outcomes, La Trobe said.

Federal Minister for Education and Training Simon Birmingham yesterday announced almost \$5 million of funding towards the La Trobe-led Australian Research Council (ARC) Industry Transformation Research Hub.

The university has committed \$10 million, with a commitment of \$6 million from industry partners.

Partners involved include The Cann Group, TPI Enterprises, HEXIMA, Olivia Newton-John Cancer Research Institute, the University of Melbourne, Under the Tree Biopharmaceuticals, SensaData, Photon Systems Instruments and Palo Alto Research Center.

Section 19A database

THE Therapeutic Goods

Administration has highlighted its database of section 19A approvals, listing medicines which are able to be imported and supplied during a shortage of other similar drugs.

The database holds information on approvals current on or after 21 Feb 2018, with a total of 38 items currently approved.

See tga.gov.au for details.

AHPRA commitment

ALL 15 health practitioner National Boards along with their Accreditation Councils and the Australian Health Practitioner Regulation Agency have signed a new Statement of Intent to achieve equity in health outcomes for Aboriginal and Torres Strait Islander people in Australia.

The document is a joint commitment with Indigenous health sector leaders, with the aim of ensuring a culturally safe health workplace and increasing the participation of Aboriginal and Torres Strait Islanders in the health professional workforce.

Tampon guidance

SPONSORS of tampon products are being alerted to updated regulatory guidance by the Therapeutic Goods Administration.

The TGA standard for tampons supplied in Australia references packaging, labelling, performance requirements, specific absorptive capacity, microbial content, withdrawal cord pull strength and water repellence - visit infostore.saiglobal.com for more details.



Events Calendar

WELCOME to *Pharmacy Daily's* events calendar, opportunities to earn CPE and CPD points.

If you have an upcoming event you'd like us to feature, email info@pharmacydaily.com.au.

9 - 10 Aug: Pharmacy WA Forum 2018 Conference and Trade Exhibition at Crown Perth. Register at eventandconfco.eventsair.com.

12 - 15 Aug: Medici Capital Pharmacy Snow Business Conference 2018; Mt Buller, Victoria; register your interest here: www.medici.com.au

7 - 8 Sep: Pharmacy Connect; Hilton Hotel Sydney; register at: www.pharmacy-connect.com.au

16 - 19 Oct: Pharmacy Alliance Members' Forum; Hamilton Island; register at Friday 03 Aug 2018: www.pamembersforum.com.au

25 - 27 Oct: Pharmacy Assistant National Conference; Sea World Resort, Gold Coast; for details see: www.pharmacyassistants.com

WIN WITH MICRODACYN

Each day this week Pharmacy Daily and **Microdacyn** are giving away **Microdacyn Hydrogel 60ml** AND **Microdacyn Solution 120ml**, valued at over \$30.

Microdacyn is the next generation hospital grade wound care that promotes rapid healing, prevents infection and reduces inflammation, now available in pharmacies. Microdacyn hydrates wounds, creating a moist environment while improving oxygen supply. The no sting and no stain formula is in an easy, no touch spray. Microdacyn is recommended for higher risk wounds including post op wounds, diabetic ulcers, burns and slow healing wounds. For more info head to: www.microdacyn.com.au

To win, be the first person from VIC or TAS to send the correct answer to the question to comp@pharmacydaily.com.au

Do international guidelines recommend Microdacyn use for higher risk wounds?

Congratulations to yesterday's winner, Michelle Clarke from Symbion.



www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor in Chief and Publisher – Bruce Piper
Managing Editor – Jon Murrie
Reporter – Mal Smith

Contributors – Jasmine O'Donoghue, Adam Bishop, Sarah Fairburn, Anastasia Prihodko
info@pharmacydaily.com.au

ADVERTISING AND MARKETING

Sean Harrigan and Melanie Tchakmadjian
advertising@pharmacydaily.com.au

BUSINESS MANAGER

Jenny Piper
accounts@pharmacydaily.com.au

Suite 1, Level 2, 64 Talavera Rd
Macquarie Park NSW 2113 Australia
PO Box 1010 Epping NSW 1710 Australia
Tel: 1300 799 220 (+61 2 8007 6760)

Sign up free at
www.pharmacydaily.com.au

Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.



New Products

- **Dolutegravir (sodium)/rilpivirine (hydrochloride) (Juluca)** contains two human immunodeficiency virus (HIV) antivirals, dolutegravir (HIV integrase inhibitor) and rilpivirine (non-competitive, diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI)). Juluca is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or integrase inhibitor. Juluca therapy should be initiated by a physician experienced in the management of HIV infection. Juluca is contraindicated in combination with the following: antiarrhythmic agent dofetilide; anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin; antimycobacterials rifampicin, rifapentine; proton pump inhibitors (such as omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole); glucocorticoid systemic dexamethasone (except as a single dose treatment); St John's wort (*Hypericum perforatum*). Juluca fixed dose combination tablets containing dolutegravir 50 mg (as dolutegravir sodium) and rilpivirine 25 mg (as rilpivirine hydrochloride) are available in packs of 30.
- **Follitropin delta (rhu) (Rekovel)** is a recombinant human follicle stimulating hormone (FSH). Differences in glycosylation profile, sialic acid pattern and isoform profile have been documented between Rekovel and other recombinant FSH products, such as follitropin alfa and follitropin beta. Rekovel is indicated in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an *in vitro* fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. Rekovel is contraindicated with the following: tumours of the hypothalamus or pituitary gland; ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome; gynaecological haemorrhages of unknown aetiology; ovarian, uterine or mammary carcinoma; pregnancy and lactation. Rekovel must not be used when an effective response cannot be obtained, such as: primary ovarian failure; malformations of sexual organs incompatible with pregnancy; fibroid tumours of the uterus incompatible with pregnancy. Rekovel contains a potent gonadotropic substance capable of causing mild to severe adverse reactions, and should only be used by physicians who are thoroughly familiar with infertility problems and their management. Rekovel solution for injection prefilled multidose pen (containing an integrated non-replaceable 3 mL cartridge) is available in strengths of 12 microgram (pack of 1 prefilled pen and 3 injection needles), 36 microgram (pack of 1 prefilled pen and 6 injection needles), and 72 microgram (pack of 1 prefilled pen and 9 injection needles).
- **Glecaprevir/pibrentasvir (Maviret)** contains two pangenotypic direct acting antivirals, glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor), targeting multiple steps in the hepatitis C virus (HCV) lifecycle. Maviret is indicated for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection, with or without compensated cirrhosis. This includes patients with HCV genotype 1 infection who were previously treated with either a regimen of an NS5A inhibitor or with an NS3/4A protease inhibitor but not both classes of inhibitors. Maviret is contraindicated with the following: severe hepatic impairment (Child-Pugh C); atazanavir containing products, atorvastatin, simvastatin, dabigatran etexilate, ethinylestradiol containing products, rifampicin. Maviret fixed dose combination tablets containing glecaprevir 100 mg and pibrentasvir 40 mg are available in packs of 84.
- **Haemophilus type b tetanus protein conjugate vaccine (Act-HIB)** contains the capsular polysaccharide of *Haemophilus influenzae* type b bacterial strain (10 microgram) conjugated to tetanus protein (18-30 microgram). The polysaccharide consists of polyribosyl ribitol phosphate (PRP). When administered to humans Act-HIB results in an IgG specific anti-PRP response in infants. Act-HIB is indicated in infants from 2 months to 5 years of age for active immunisation against invasive disease caused by *Haemophilus influenzae* type b. The vaccine does not protect against infections due to other types of *Haemophilus influenzae* nor against meningitis from other origins. Note: under no circumstances should the tetanus protein component of this vaccine be substituted for the routine tetanus vaccination. Act-HIB is contraindicated with the following: known systemic hypersensitivity to any component of Act-HIB in particular the tetanus protein or formaldehyde; life threatening reaction after previous administration of the vaccine or vaccine containing the same substances; vaccination must be postponed in case of febrile or acute disease. Act-HIB powder for reconstitution (10 microgram vial) with diluent for injection (0.5 mL syringe) is available in a pack of 1.
- **Insulin degludec/insulin aspart (rys) (Ryzodeg 70/30)** is a soluble insulin analogue product consisting of ultra-long acting basal insulin degludec and rapid acting prandial (mealtime) insulin aspart. Ryzodeg 70/30 can be administered once or twice daily with the main meal(s). When needed, the patient can change the time of administration as long as Ryzodeg 70/30 is dosed with the largest meal when taken once daily. Ryzodeg 70/30 is indicated to improve glycaemic control in adults with diabetes mellitus requiring basal and prandial insulin. Ryzodeg 70/30 FlexTouch solution for injection prefilled multidose disposable pen (containing 3 mL cartridge) is available in pack sizes 1 x 3 mL, 5 x 3 mL. Ryzodeg 70/30 Penfill solution for injection (3 mL cartridge) is available in pack size 5 x 3 mL.

New Indications

- **Denosumab (rch) (Prolia)** is now indicated to increase bone mass in women and men at increased risk of fracture due to long-term systemic glucocorticoid therapy.
- **Ixekizumab (rch) (Taltz)** is now indicated for the treatment of active psoriatic arthritis in adults who have responded inadequately, or who are intolerant, to previous DMARD therapy. Taltz may be used as monotherapy or in combination with a conventional DMARD (e.g. methotrexate).
- **Nepafenac (Ilevro)** is now indicated for the reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non-proliferative diabetic retinopathy.

- **Pembrolizumab (Keytruda)** in combination with pemetrexed and platinum chemotherapy is now indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC).
- **Trametinib (Mekinist)** in combination with dabrafenib is now indicated for the adjuvant treatment of melanoma with a BRAF V600 mutation and involvement of the lymph node(s), following complete resection.

New Contraindications

- **Clarithromycin (Klacid)** is now contraindicated with concurrent administration of domperidone.
- **Diclofenac sodium (Voltaren)** and **diclofenac potassium (Voltaren Rapid)** are now contraindicated in patients in whom diclofenac, aspirin or other NSAIDs induce angioedema.
- **Eicosapentaenoic acid (EPA) ethyl ester/docosahexaenoic acid (DHA) ethyl ester (Omacor)** is now contraindicated with hypersensitivity to peanut.
- **Eliglustat (Cerdega)** is now contraindicated in the following: CYP2D6 intermediate metabolisers or poor metabolisers with any degree of hepatic impairment, since metabolism is the predominant route of elimination; CYP2D6 extensive metabolisers (EMs) with moderate or severe hepatic impairment and in CYP2D6 EMs with mild hepatic impairment taking a strong or moderate CYP2D6 inhibitor.

*This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.*

Biosimilar Awareness Initiative

The Biosimilar Awareness Initiative by the Department of Health is intended to support awareness of, and confidence in, the use of biosimilar medicines for healthcare professionals and consumers.

Information about the Initiative can be found on the Department of Health website:

<http://www.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-awareness-initiative>